HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P V Barnett Selected Research

Foot-and-Mouth Disease

8/2015A Review of OIE Country Status Recovery Using Vaccinate-to-Live Versus Vaccinate-to-Die Foot-and-Mouth Disease Response Policies I: Benefits of Higher Potency Vaccines and Associated NSP DIVA Test Systems in Post-Outbreak Surveillance.
8/2015A Review of OIE Country Status Recovery Using Vaccinate-to-Live Versus Vaccinate-to-Die Foot-and-Mouth Disease Response Policies II: Waiting Periods After Emergency Vaccination in FMD Free Countries.
4/2012A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease.
10/2011Foot-and-mouth disease marker vaccine: cattle protection with a partial VP1 G-H loop deleted virus antigen.
12/2010Toward a global foot and mouth disease vaccine bank network.
4/2010Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion.
4/2008Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle.
1/2008Evaluation of a monoclonal antibody-based approach for the selection of foot-and-mouth disease (FMD) vaccine strains.
1/2008FMD vaccines: reflections on quality aspects for applicability in European disease control policy.
7/2006Porcine gammadelta T cells: possible roles on the innate and adaptive immune responses following virus infection.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


P V Barnett Research Topics

Disease

21Foot-and-Mouth Disease
08/2015 - 02/2001
7Infections
10/2011 - 02/2002
1Tuberculosis (Tuberculoses)
02/2006

Drug/Important Bio-Agent (IBA)

19VaccinesIBA
08/2015 - 02/2001
5AntigensIBA
10/2011 - 02/2001
3AerosolsIBA
04/2006 - 03/2004
2Proteins (Proteins, Gene)FDA Link
04/2012 - 05/2005
2AntibodiesIBA
10/2011 - 10/2005
1DNA (Deoxyribonucleic Acid)IBA
04/2012
1A-Form DNA (A-DNA)IBA
04/2012
1Marker VaccinesIBA
10/2011
1Inactivated VaccinesIBA
01/2008
1Monoclonal AntibodiesIBA
01/2008
1Immunoglobulin G (IgG)IBA
05/2005
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
01/2005